14-day Premium Trial Subscription Try For FreeTry Free
$1.37
+0.0700 (+5.38%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.22 $1.62 Friday, 3rd May 2024 AKBA stock ended at $1.37. This is 5.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 7.58% from a day low at $1.32 to a day high of $1.42.
90 days $1.22 $2.47
52 weeks $0.780 $2.47

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Feb 22, 2023 $0.674 $0.719 $0.670 $0.692 1 419 344
Feb 21, 2023 $0.82 $0.85 $0.620 $0.654 3 934 957
Feb 17, 2023 $0.84 $0.89 $0.81 $0.88 1 034 084
Feb 16, 2023 $0.88 $0.89 $0.84 $0.86 542 377
Feb 15, 2023 $0.89 $0.91 $0.81 $0.89 1 544 495
Feb 14, 2023 $0.764 $0.85 $0.764 $0.85 1 149 023
Feb 13, 2023 $0.85 $0.90 $0.751 $0.793 1 929 982
Feb 10, 2023 $1.06 $1.11 $0.570 $0.80 14 803 232
Feb 09, 2023 $1.19 $1.19 $1.11 $1.12 1 710 883
Feb 08, 2023 $1.12 $1.20 $1.09 $1.15 1 844 199
Feb 07, 2023 $1.10 $1.15 $0.99 $1.13 2 968 324
Feb 06, 2023 $0.99 $1.18 $0.99 $1.07 4 058 994
Feb 03, 2023 $0.85 $0.99 $0.84 $0.99 2 817 586
Feb 02, 2023 $0.743 $0.95 $0.730 $0.89 8 591 731
Feb 01, 2023 $0.635 $0.690 $0.620 $0.670 1 403 855
Jan 31, 2023 $0.610 $0.653 $0.610 $0.630 1 102 101
Jan 30, 2023 $0.668 $0.675 $0.600 $0.604 1 816 084
Jan 27, 2023 $0.700 $0.718 $0.560 $0.670 2 642 750
Jan 26, 2023 $0.730 $0.730 $0.701 $0.710 1 737 203
Jan 25, 2023 $0.710 $0.730 $0.710 $0.712 1 074 694
Jan 24, 2023 $0.710 $0.750 $0.701 $0.722 1 400 125
Jan 23, 2023 $0.737 $0.737 $0.701 $0.710 915 213
Jan 20, 2023 $0.700 $0.745 $0.690 $0.737 1 194 736
Jan 19, 2023 $0.744 $0.744 $0.672 $0.709 1 434 731
Jan 18, 2023 $0.728 $0.770 $0.710 $0.719 1 631 937
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT